Table 3 The frequency of adverse events in each group of the bSS.
n (%) | Group B N = 196 | Group C N = 190 | Group E N = 190 | Group F N = 184 | *P-value |
|---|---|---|---|---|---|
AEs | 23 (11.73%) | 32 (16.84%) | 10 (5.26%) | 23 (12.5%) | 0.0035 |
ARs | 22 (11.22%) | 30 (15.79%) | 7 (3.68%) | 20 (10.87%) | 0.0007 |
Inject-site AEs | 18 (9.18%) | 23 (12.11%) | 6 (3.16%) | 17 (9.24%) | 0.0080 |
 Pain | 16 (8.16%) | 23 (12.11%) | 6 (3.16%) | 17 (9.24%) |  |
 Induration | 0 | 1 (0.53%) | 0 | 0 |  |
 Redness | 1 (0.51%) | 2 (1.05%) | 1 (0.53%) | 0 |  |
 Swelling | 0 | 2 (1.05%) | 1 (0.53%) | 4 (2.17%) |  |
 Itch | 3 (1.53%) | 0 | 1 (0.53%) | 1 (0.54%) |  |
 Rash | 0 | 0 | 0 | 0 |  |
Systemic AEs | 9 (4.59%) | 11 (5.79%) | 3 (1.58%) | 6 (3.26%) | 0.1461 |
 Fever | 5 (2.55%) | 6 (3.16%) | 2 (1.05%) | 3 (1.63%) |  |
 Fatigue | 3 (1.53%) | 5 (2.63%) | 0 | 2 (1.09%) |  |
 Headache | 1 (0.51%) | 1 (0.53%) | 1 (0.53%) | 2 (1.09%) |  |
 Dizziness | 1 (0.51%) | 3 (1.58%) | 0 | 2 (1.09%) |  |
 Vomiting | 0 | 1(0.53%) | 0 | 0 |  |
 Bellyache | 0 | 2 (1.05%) | 0 | 0 |  |
 Diarrhea | 0 | 1 (0.53%) | 0 | 0 |  |
 Myalgia | 2 (1.02%) | 1 (0.53%) | 0 | 0 |  |
 Arthralgia | 0 | 0 | 0 | 0 |  |
 Acute allergic reaction | 0 | 0 | 0 | 0 |  |
